EMA PERSPECTIVES/CLINICAL TRIALS & FRAILTY
In December of 2015, the EMA released a draft working paper titled “Points to consider on frailty: Evaluation instruments for baseline characteristics of clinical trial populations.” Among other considerations, this working paper includes the short physical performance battery (SPPB) and gait speed as measures of possible use in identifying vulnerable populations at risk of adverse outcomes. This webinar will feature an overview of the working paper as well as the EMA geriatric strategy.
Francesca Cerreta (Link)
Senior Scientific Officer
European Medicines Agency (EMA).
Executive Director, Aging in Motion Coalition
Vice President of Public Policy
Alliance for Aging Research